Others have shown that a decrease in on-treatment CRP correlates with improved PFS and responses to ICI in metastatic NSCLC.45 Similarly, a reduction in CRP during atezolizumab treatment for NSCLC was a strong surrogate for numerical PFS/OS benefit and better responses in both the OAK/POPLAR cohort and the B-F1RST trial.46 47 Thus, both baseline and on-treatment changes in CRP could serve as a biomarker for ICI-based approaches. This evidence concerns the gene CRP and non-small cell lung carcinoma.